During the entire anniversary month, Cirrus will hold a series of events that reflect on its history, growth, contributions to pharmaceutical research and development, and its appreciation to the business community and its employees.

"None of this growth would have been possible without the tremendous efforts of all our employees and the respect and confidence Cirrus has gained by serving its clients needs and providing them with timely solutions," stated co-founder Dr. Anthony Hickey, who serves as Cirrus's President and CEO.

Cirrus's keynote event for its 10^th anniversary will take place on Tuesday, June 12^th from 2 p.m. to 6 p.m. with an Open House reception. Highlights include talks by the Senior Advisor to the Governor for Science and Technology, Dr. Robert McMahan, and President and CEO of Inspire Pharmaceuticals, Dr. Christy Shaffer. When Cirrus opened its doors in 1997, Inspire Pharmaceuticals was their first client.

Paul McGlynn, Senior Director of Aerosol Product Development of long-time Cirrus client Sepracor, Inc. added, "Since 1999, Cirrus has been a preferred partner for our Aerosol Development group at Sepracor. Our success comes from a spirit of collaboration between our two companies which is the same now as it was when we started working together". Cirrus helped Sepracor in the formulation of Sepracor's drug Xopenex HFA® which treats asthma and chronic obstructive pulmonary diseases (COPD) and the formulation led to the successful Xopenex HFA® product launch in January 2006.

The Research Triangle-based Cirrus Pharmaceuticals ranked 13^th on the list of top 50 companies. The rankings were determined by PricewaterhouseCoopers LLP, who evaluated locally headquartered private companies based on a formula that takes into account both dollar growth and percentage rate of growth over a three-year period. To be considered companies were required to have had at least $3 million in revenue in 2005.

"Cirrus success stems from the collaborative research environment we have fostered with our clients and employees. This collaborative environment provides both the client and Cirrus' staff the flexibility to make quick decisions thus making the drug development process shorter and less expensive in the long-run. This award is also a testament to the quality of service Cirrus provides its clients as well as to the quality of employees at Cirrus" says Dr. Tony Hickey, CEO & President.

XOPENEX HFA is an HFA MDI that is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children 4 years of age and older with reversible obstructive airway disease. Reversible obstructive airway disease includes respiratory disorders such as asthma and the reversible component of chronic obstructive pulmonary disease.

Cirrus' contributions to the development of XOPENEX HFA included assistance with pre-formulation studies, device selection, development of the HFA formulation, and manufacturing process development. XOPENEX HFA received regulatory approval in the shortest FDA review cycle for an HFA MDI to date.

"Cirrus is a leader in the field in terms of being able to create new opportunities in reformulating drugs," observes Brian Leedman, a spokesman in pSivida's Perth headquarters. "We're looking for opportunities to reformulate our BioSilicon™ technology, so this collaboration represents a faster way to market."

"The Cirrus collaboration represents an extended use of another company's facilities to conduct further experimentation," Leedman says. "We see this as a cost-effective way to expand our product portfolio."

"This new collaboration represents a further significant commitment and investment by pSivida in the core area of our business, which leverages a critical U.S.-based, FDA-experienced development resource" adds Gavin Rezos, the company's managing director.

Co-founder and Executive Senior Vice President Dr. Jean-Marc Bovet, attributes the growth of the company to its focus on providing timely research and project development support to the pharmaceutical industry and to the diverse professional and educational backgrounds of the staff. Jean-Marc also expressed his appreciation for each employee's hard work in making this growth possible.